Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02PBY
|
||||
Former ID |
DNC006933
|
||||
Drug Name |
3-noradamantyl-1,3-dipropylxanthine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [528544] | ||
Structure |
Download2D MOL |
||||
Formula |
C20H28N4O2
|
||||
Canonical SMILES |
CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CC5CC(C3)C(C5)C4
|
||||
InChI |
1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-9-12-7-13(10-20)14(8-12)11-20/h12-14H,3-11H2,1-2H3,(H,21,22)
|
||||
InChIKey |
IDHJABAMUQNMKF-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Adenosine A1 receptor | Target Info | Inhibitor | [528544] | |
Adenosine A2b receptor | Target Info | Inhibitor | [528544] | ||
Adenosine A2a receptor | Target Info | Inhibitor | [528544] | ||
Adenosine A3 receptor | Target Info | Inhibitor | [528544] | ||
KEGG Pathway | cGMP-PKG signaling pathway | ||||
cAMP signaling pathway | |||||
Sphingolipid signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Morphine addictionhsa04015:Rap1 signaling pathway | |||||
Calcium signaling pathway | |||||
Vascular smooth muscle contraction | |||||
Alcoholismhsa04015:Rap1 signaling pathway | |||||
Parkinson's disease | |||||
Alcoholism | |||||
Pathway Interaction Database | C-MYB transcription factor networkhif2pathway:HIF-2-alpha transcription factor network | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.